The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis
Open accessAbstract
Background Intravenous-busulfan (IV-busulfan) combined with therapeutic drug monitoring to guide dosing improves outcomes after allogeneic hematopoietic cell transplantation (allo-HCT). The best method to estimate busulfan exposure and the optimal exposure in children/young adults remains unclear. We therefore evaluated three approaches to estimate IV-Bu exposure (expressed as cumulative-area-under-the-curve; AUC) and associated busulfan-AUC with clinical outcomes in children/young adults undergoing allo-HCT. Methods In this retrospective analysis, patients (0.1–30.4 years) receiving busulfan-based conditioning regimen from 15 centers were included. Cumulative AUC was calculated by numerical integration using non-linear mixed effect modeling (AUCNONMEM), non-compartmental analysis (AUC0-infinity and AUC to the end of the dose interval AUC0-tau) and by individual centers using a variety of approaches (AUCcenter). Main outcome of interest was event-free survival (EFS). Other outcomes of interest were overall survival, graft-failure, relapse, transplantation related mortality (TRM), acute toxicity (veno-occlusive disease (VOD) and/or acute graft versus-host disease (aGvHD), chronic GvHD (cGvHD) and cGVHD-free event-free survival (GEFS). Propensity score adjusted cox proportional hazard models, Weibull models, and Fine-Gray competing risk regressions were used. Results 674 patients were included (41% malignant, 59% non-malignant) Estimated 2-year EFS was 69.7%. The median busulfan AUCNONMEM was 74.4 mg*h/L (CI95% 31.1–104.6 mg*h/L). The median AUCNONMEM correlated poorly with AUCcenter (R2 = 0.254). Patients with optimal IV-busulfan AUC of 78–101 mg*h/L showed 81% EFS at 2 years compared to 66.1% and 49.5% in the low (<78 mg*h/L) and high (>101 mg*h/L) busulfan AUC group respectively (P=0.011). Graft-failure/relapse occurred more frequently in the low AUC group (HR=1.75 P<0.001). Acute toxicity, cGvHD and TRM was significantly higher in the high AUC group (HR 1.69, 2.99 and 1.30), independent of indication. Interpretation These results demonstrate that improved clinical outcomes may be achieved by targeting the busulfan-AUC to 78–101 mg*h/L using a new validated pharmacokinetic-model for all indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GLUCKSBERG, H., STORB, R., FEFER, A., BUCKNER, C. D., NEIMAN, P. E., CLIFT, R. A., LERNER, K. G., & THOMAS, E. D. (1974) · Transplantation · doi:10.1097/00007890-197410000-00001 · Cited by 3,694
Chronic graft-versus-host syndrome in man
Shulman, H. M., Sullivan, K. M., Weiden, P. L., McDonald, G. B., Striker, G. E., Sale, G. E., Hackman, R., Tsoi, M.-S., Storb, R., & Donnall Thomas, E. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90380-0 · Cited by 2,406
Sampling of Populations: Methods and Applications
Ziegel, E. R., Levy, P., & Lemeshaw, S. (1992) · Technometrics · doi:10.2307/1270072 · Cited by 1,250
Sessa, M., Lorioli, L., Fumagalli, F., Acquati, S., Redaelli, D., Baldoli, C., Canale, S., Lopez, I. D., Morena, F., Calabria, A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30374-9 · Cited by 502
Güngör, T., Teira, P., Slatter, M., Stussi, G., Stepensky, P., Moshous, D., Vermont, C., Ahmad, I., Shaw, P. J., da Cunha, J. M. T., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62069-3 · Cited by 377
Self-citationCorbacioglu, S., Cesaro, S., Faraci, M., Valteau-Couanet, D., Gruhn, B., Rovelli, A., Boelens, J. J., Hewitt, A., Schrum, J., Schulz, A. S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61938-7 · Cited by 375
Self-citationSlattery, J. T., Clift, R. A., Buckner, C. D., Radich, J., Storer, B., Bensinger, W. I., Soll, E., Anasetti, C., Bowden, R., Bryant, E., et al. (1997) · Blood · doi:10.1182/blood.v89.8.3055 · Cited by 351
Sampling of Populations: Methods and Applications.
Cohen, G. R., Levy, P. S., Lemeshow, S., Hedayat, A. S., & Sinha, B. K. (1992) · Biometrics · doi:10.2307/2532723 · Cited by 330
Association of busulfan area under the curve with veno-occlusive disease following BMT.
Dix, S. P., Wingard, J. R., Mullins, R. E., Jerkunica, I., Davidson, T. G., Gilmore, C. E., York, R., Lin, L., Devine, S. M., Geller, R. B., et al. (1996) · PubMed · Cited by 311
Admiraal, R., van Kesteren, C., Jol-van der Zijde, C. M., Lankester, A. C., Bierings, M. B., Egberts, T. C. G., van Tol, M. J. D., Knibbe, C. A. J., Bredius, R. G. M., & Boelens, J. J. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00045-9 · Cited by 292
Self-citation
Cited by
Mohty, M., Malard, F., Abecassis, M., Aerts, E., Alaskar, A. S., Aljurf, M., Arat, M., Bader, P., Baron, F., Bazarbachi, A., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.130 · Cited by 543
Corbacioglu, S., Carreras, E., Ansari, M., Balduzzi, A., Cesaro, S., Dalle, J.-H., Dignan, F., Gibson, B., Guengoer, T., Gruhn, B., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.161 · Cited by 363
Self-citationMöhlmann, J. E., Ezzafzafi, S., Lindemans, C. A., Jansen, M. H. A., Nierkens, S., Huitema, A. D. R., & van Luin, M. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01419-7 · Cited by 33
Harris, A. C., Boelens, J. J., Ahn, K. W., Fei, M., Abraham, A., Artz, A., Dvorak, C., Frangoul, H., Freytes, C., Gale, R. P., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018016956 · Cited by 33
Self-citationYoushani, A. S., Rowlston, S., O’Leary, C., Forte, G., Parker, H., Liao, A., Telfer, B., Williams, K., Kamaly-Asl, I. D., & Bigger, B. W. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1410-y · Cited by 16
Metadata
- Authors
- Bartelink, I. H., Lalmohamed, A., van Reij, E. M. L., Dvorak, C. C., Savic, R. M., Zwaveling, J., Bredius, R. G. M., Egberts, A. C. G., Bierings, M., Kletzel, M., Shaw, P. J., Nath, C. E., Hempel, G., Ansari, M., Krajinovic, M., Théorêt, Y., Duval, M., Keizer, R. J., Bittencourt, H., Hassan, M., Güngör, T., Wynn, R. F., Veys, P., Cuvelier, G. D. E., Marktel, S., Chiesa, R., Cowan, M. J., Slatter, M. A., Stricherz, M. K., Jennissen, C., Long-Boyle, J. R., & Boelens, J. J.
- Venue
- The Lancet Haematology
- Publisher
- Elsevier BV
- Published
- 2016-11
- Volume
- 3
- Issue
- 11
- Pages
- e526-e536
- ISSN
- 2352-3026 (ISSN-L)
- OpenAlex
- W2530375062
- Cited by
- 294
- References
- 18
- FWCI
- 14.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. https://app.cochat.ai/papers/10.1016/s2352-3026(16)30114-4
- The paper
- Bartelink, I. H., Lalmohamed, A., van Reij, E. M. L., Dvorak, C. C., Savic, R. M., Zwaveling, J., Bredius, R. G. M., Egberts, A. C. G., Bierings, M., Kletzel, M., Shaw, P. J., Nath, C. E., Hempel, G., Ansari, M., Krajinovic, M., Théorêt, Y., Duval, M., Keizer, R. J., Bittencourt, H., . . . Boelens, J. J. (2016). Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(16)30114-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.